UK markets closed
  • FTSE 100

    7,051.48
    -26.87 (-0.38%)
     
  • FTSE 250

    23,608.79
    -221.39 (-0.93%)
     
  • AIM

    1,266.98
    -5.42 (-0.43%)
     
  • GBP/EUR

    1.1666
    -0.0017 (-0.15%)
     
  • GBP/USD

    1.3670
    -0.0051 (-0.37%)
     
  • BTC-GBP

    31,042.91
    -1,882.24 (-5.72%)
     
  • CMC Crypto 200

    1,054.79
    -48.27 (-4.38%)
     
  • S&P 500

    4,459.92
    +10.94 (+0.25%)
     
  • DOW

    34,830.25
    +65.43 (+0.19%)
     
  • CRUDE OIL

    73.98
    +0.68 (+0.93%)
     
  • GOLD FUTURES

    1,747.60
    -2.20 (-0.13%)
     
  • NIKKEI 225

    30,248.81
    +609.41 (+2.06%)
     
  • HANG SENG

    24,192.16
    -318.82 (-1.30%)
     
  • DAX

    15,531.75
    -112.22 (-0.72%)
     
  • CAC 40

    6,638.46
    -63.52 (-0.95%)
     

Will Moderna’s Tenure on the S&P 500 Index Be Short-Lived?

·5-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Moderna (NASDAQ: MRNA) is now officially a member of the S&P 500. In this Motley Fool Live video recorded on July 21, 2021, healthcare and cannabis bureau editor-analyst Olivia Zitkus and Motley Fool contributor Keith Speights discuss whether or not Moderna's tenure on the S&P 500 index will be short-lived. Let's go over to Moderna, which is now officially, I think today, a member of the S&P 500 Index.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting